Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
October 29, 2021 17:45 ET
|
BioNTech SE
Emergency Use Authorization (EUA) is supported by clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 through 11 years of age during a period when Delta...
Pfizer und BioNTech beliefern U.S.-Regierung mit 50 Millionen weiteren Kinderimpfdosen des COVID-19-Impfstoffs zur Vorbereitung auf zukünftigen Bedarf
October 28, 2021 06:58 ET
|
BioNTech SE
Impfdosen werden vermutlich bis April 2022 geliefert NEW YORK und MAINZ, Deutschland, 28. Oktober 2021 — Pfizer Inc. (NYSE: PFE, “Pfizer”) und BioNTech SE (Nasdaq: BNTX, “BioNTech”) gaben heute...
Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
October 28, 2021 06:58 ET
|
BioNTech SE
Doses expected to be delivered by April 2022 NEW YORK and MAINZ, GERMANY, October 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has...
BioNTech veröffentlicht am 9. November 2021 Ergebnisse des dritten Quartals sowie Informationen zum operativen Fortschritt
October 27, 2021 07:00 ET
|
BioNTech SE
MAINZ, Deutschland, 27. Oktober 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen“) wird am Dienstag, den 9. November 2021, die Ergebnisse des dritten Quartals 2021...
BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
October 27, 2021 07:00 ET
|
BioNTech SE
Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter on Tuesday, November 9th, 2021....
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
October 26, 2021 18:19 ET
|
BioNTech SE
Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 years of age during a period when Delta was the prevalent strain10-µg...
BioNTech plant Mitte 2022 den Baubeginn einer mRNA Impfstoff-Produktionsstätte in Afrika
October 26, 2021 08:00 ET
|
BioNTech SE
BioNTech unterzeichnet eine Absichtserklärung mit der ruandischen Regierung und dem Institut Pasteur de Dakar. Der Baubeginn für die erste mRNA-Produktionsstätte in Afrika ist für Mitte 2022...
BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022
October 26, 2021 08:00 ET
|
BioNTech SE
BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is planned to be initiated in...
Daten aus Phase-3-Studie von Pfizer und BioNTech zeigen hohe Wirksamkeit von COVID-19-Auffrischungsimpfung
October 21, 2021 06:45 ET
|
BioNTech SE
Die ersten Ergebnisse einer randomisierten, kontrollierten COVID-19 Impfstoff-Auffrischungsstudie zeigen eine relative Impfstoffwirksamkeit von 95,6 % gegen COVID-19 in einem Zeitraum, in dem Delta...
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
October 21, 2021 06:45 ET
|
BioNTech SE
First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain In...